Physician profile
Michael Barris
NPI 1386671204
$2,889.01
in general payments reported to CMS, 2019-2025
21 companies · $190 in 2025
The $190 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $186 · 2021: $161 · 2022: $201 · 2023: $1,399 · 2024: $545 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.76 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $552.49 | 2019-2024 | Farxiga, Breztri, Lynparza |
| Pfizer INC. | $507.93 | 2022-2025 | |
| Abbvie INC. | $390.00 | 2022-2024 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $304.80 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $211.68 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $189.61 | 2023-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.46 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $117.98 | 2022-2025 | |
| Radius Health, INC. | $104.47 | 2022-2024 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.50 | 2021-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $64.03 | 2023-2024 | |
| Exact Sciences Corporation | $52.03 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $35.78 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $28.46 | 2023 | Trintellix |
| Amgen INC. | $28.33 | 2023-2025 | Repatha, Otezla, Repatha |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $21.48 | 2023 | Nuzyra |
| Alexion Pharmaceuticals, INC. | $16.62 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.78 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.39 | 2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $13.27 | 2023 | Quviviq |
| Amarin Pharma, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.